| abstract |
Compounds derived from administration of torcetrapib to mammals, and use of such compounds as indicators or biomarkers that indicate the presence or exposure of torcetrapib in the plasma of mammals, including humans. The present invention also includes cholesterol ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors, and certain plasmas of such inhibitors, including high density lipoprotein (HDL) -cholesterol. It also relates to use to increase lipid concentration and lower certain other plasma lipid concentrations such as low density lipoprotein (LDL) -cholesterol and triglycerides. |